New England Journal of Medicine | June 2026
All-Oral Therapy Improves Outcomes in AML Patients
This study investigates the safety and efficacy of an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed acute myeloid leukemia, showing a 47% complete response rate and improved survival with manageable side effects.